en
Scientific article
Review
Open access
English

Revisiting the interleukin 17 family of cytokines in psoriasis : pathogenesis and potential targets for innovative therapies

Published inFrontiers in immunology, vol. 14, 1186455
Publication date2023
First online date2023-05-22
Abstract

Psoriasis is a common chronic inflammatory skin disease, associated with substantial comorbidity. TH17 lymphocytes, differentiating under the influence of dendritic cell-derived IL-23, and mediating their effectsviaIL-17A, are believed to be central effector cells in psoriasis. This concept is underlined by the unprecedented efficacy of therapeutics targeting this pathogenetic axis. In recent years, numerous observations made it necessary to revisit and refine this simple "linear" pathogenetic model. It became evident that IL-23 independent cells exist that produce IL-17A, that IL-17 homologues may exhibit synergistic biological effects, and that the blockade of IL-17A alone is clinically less effective compared to the inhibition of several IL-17 homologues. In this review, we will summarize the current knowledge around IL-17A and its five currently known homologues, namely IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25) and IL-17F, in relation to skin inflammation in general and psoriasis in particular. We will also re-visit the above-mentioned observations and integrate them into a more comprehensive pathogenetic model. This may help to appreciate current as well as developing anti-psoriatic therapies and to prioritize the selection of future drugs' mode(s) of action.

eng
Keywords
  • IL-17
  • IL-25
  • TH17 cells
  • TYK2
  • Psoriasis
  • Psoriatic arthritis
  • Humans
  • Interleukin-17
  • Cytokines
  • Psoriasis / drug therapy
  • Psoriasis / etiology
  • Dermatitis / complications
  • Therapies, Investigational / adverse effects
  • Interleukin-23
Citation (ISO format)
BREMBILLA, Nicolo, BOEHNCKE, Wolf-Henning. Revisiting the interleukin 17 family of cytokines in psoriasis : pathogenesis and potential targets for innovative therapies. In: Frontiers in immunology, 2023, vol. 14, p. 1186455. doi: 10.3389/fimmu.2023.1186455
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1664-3224
12views
2downloads

Technical informations

Creation12/22/2023 7:56:49 AM
First validation04/08/2024 8:36:41 AM
Update time04/08/2024 8:36:41 AM
Status update04/08/2024 8:36:41 AM
Last indexation05/06/2024 6:20:27 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack